CSF3 and cardiomyopathy: Given the patient was not a candidate for anthracycline-containing therapy due to baseline cardiomyopathy with reduced ejection fraction (34%), he was treated with six cycles of rituximab, gemcitabine, cyclophosphamide, vincristine, and prednisone (R-GCVP) with granulocyte colony-stimulating factor (G-CSF).